Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Using biomarkers to identify molecular lesions and monitor response to treatment in multiple myeloma

Gareth Morgan • 25 Aug 2022
IMS 2022
Multiple Myeloma

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, comments on the use of biomarkers to identify molecular lesions including mutations, translocations, and amplifications in patients with multiple myeloma, and to monitor treatment response with the aim to tailor therapies to each patient. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gareth Morgan

2:19
How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan • 10 Dec 2023
1:48
Investigating the non-coding myeloma genome
Gareth Morgan • 10 Dec 2023
1:29
Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Gareth Morgan • 10 Dec 2023
1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals